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Abstract
Objectives: This study aimed to illustrate the indications for, and types and outcomes of surgical
portosystemic shunt (PSS) and/or Rex bypass in a single centre.
Methods: Data were collected from children with a PSS and/or Rex bypass between 1992 and 2006 at
Mount Sinai Medical Center, New York.
Results: Median age at surgery was 10.7 years (range 0.3–22.0 years). Indications included: (i) refractory
gastrointestinal bleeding in portal hypertension associated with (a) compensated cirrhosis (n = 12), (b)
portal vein thrombosis (n = 10), (c) hepatoportal sclerosis (n = 3); (ii) refractory ascites secondary to
Budd–Chiari syndrome (n = 3), and (iii) familial hypercholesterolaemia (n = 4). There were 20 distal
splenorenal, four portacaval, three Rex bypass, two mesocaval, two mesoatrial and one proximal sple-
norenal shunts. At the last follow-up (median 2.9 years, range 0.1–14.1 years), one shunt (Rex bypass)
was thrombosed. Two patients had died and two had required a liver transplant. These had a patent shunt
at last imaging prior to death or transplant.
Conclusions: Portosystemic shunts and Rex bypass have been used to manage portal hypertension
with excellent outcomes. In selected children with compensated liver disease, PSS may act as a bridge
to liver transplantation or represent an attractive alternative.
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Introduction
Portal hypertension is defined by a pathological increase in portal
pressure in which the pressure gradient between the portal vein
and inferior vena cava (portal pressure gradient) is increased
above the upper normal limit of 5 mmHg.1 An evidence-based
approach for the management of portal hypertension in children
does not exist. A panel of paediatric experts recently reviewed the
most recent Baveno statement on management of portal hyper-
tension in adults and modified it to be applicable to the paediatric
setting.2 Portosystemic shunt (PSS) and Rex bypass have been
performed in children with extrahepatic portal vein thrombosis
when variceal bleeding is refractory to medical or endoscopic
therapy.When there is intrinsic liver disease, the selection of can-
didates for PSS as opposed to transjugular intrahepatic portosys-
temic shunt (TIPS) or liver transplantation (LTx) requires careful
consideration.
Portosystemic shunt can be non-selective (decompressing all
portal hypertension; e.g. side-to-side portacaval, mesocaval and
proximal splenorenal shunts) or selective (decompressing gastro-
oesophageal varices through the short gastric veins, spleen and
splenic vein to left renal vein, but maintaining the superior
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mesenteric vein flow to the liver, described as distal splenorenal
shunt [DSRS] by Warren et al.3). The TIPS is a side-to-side PSS
placed radiographically in the liver parenchyma joining the portal
and hepatic veins. This technique emerged in the early 1990s as an
alternative to surgical shunts. The encephalopathy rate after TIPS
appears to be similar to that after non-selective surgical shunts.4
Although expertise in TIPS in adults is not uncommon, the pro-
cedure can be technically difficult in children, especially in chil-
dren aged <5 years. The smaller size of the venous structures and
liver and the presence of anatomic variants are limiting factors for
success in paediatric patients.5
The superior mesenteric vein to left portal vein (Rex) bypass is
described as re-directing the portal flow into the liver, and there-
fore should not, either anatomically or physiologically, be consid-
ered a shunt procedure.6,7 This operation restores portal flow by
bringing mesenteric venous and splenic blood around the extra-
hepatic portal obstruction into a patent intrahepatic portal
venous system. This restoration of the physiological hepatopedal
flow may result in both developmental and neurological benefits
in children.7,8 The present study reviews a single-centre experience
of surgical PSS and Rex bypass procedures in children with respect
to diagnosis, selection of candidates, type of surgical procedure,
management and outcome.
Materials and methods
A retrospective chart review of patients presenting from January
1992 to December 2006 was undertaken after institutional review
board approval. Data were collected from all patients seen in the
paediatric liver programme who received a PSS and/or Rex bypass
at Mount Sinai Medical Center, NewYork. Data collected included
age, gender, diagnosis, type of surgical procedure and outcome.
The aetiology of portal hypertension in children who received a
PSS and/or Rex bypass was documented. In children with intrinsic
liver disease, details of liver function tests were obtained to docu-
ment the indication for PSS as opposed to LTx. In children with
familial hypercholesterolaemia, information regarding ongoing
treatment with lipid-lowering agents was also obtained. At last
follow-up, information was collected regarding patency of shunt
and need for transplantation. A shunt noted to be patent on
imaging studies was considered to be a functioning shunt.
Surgical techniques and postoperative care
Surgical techniques for the various shunt procedures have been
published in detail before.9–12 In the Rex bypass, the internal
jugular vein of the patient was used as a conduit (Fig. 1). In one
case where the internal jugular vein was not available, an 8F
gortex graft was used. Rex bypass was performed from Decem-
ber 2004 onwards in this series. For mesoatrial shunt cases, 12F
ring gortex grafts were used as conduits. In all surgical shunts,
special care was taken to avoid kinking or twisting at the anas-
tomosis. Interrupted sutures were used to avoid anastomotic
stricture. Patients were anticoagulated postoperatively with low
molecular weight heparin and aspirin in the short-term and
aspirin alone in the longterm. Those with a pro-coagulant status
were continued on low molecular weight heparin longterm.
Children with familial hypercholesterolaemia were not given
aspirin in the longterm as they were anticoagulated regularly as
part of ongoing apheresis therapy.
Results
Thirty-two patients including two following LTx received a PSS
and/or Rex bypass in our paediatric liver programme between
January 1992 andDecember 2006. Indications included: (i) refrac-
tory gastrointestinal bleeding in portal hypertension associated
with (a) compensated cirrhosis (n = 12), (b) portal vein throm-
bosis (n = 10), (c) hepatoportal sclerosis (n = 3); (ii) refractory
ascites secondary to Budd–Chiari syndrome (n = 3), and (iii)
familial hypercholesterolaemia (n = 4). There were 20 distal sple-
norenal, four portacaval, three Rex bypass, two mesocaval, two
mesoatrial and one proximal splenorenal shunts. Median patient
age at surgery was 10.7 years (range 0.3–22 years) and 22 patients
were male. Fifteen patients were aged <10 years at surgery and
eight were aged <5 years.
Twelve (patients 1–12) with intrinsic liver disease underwent
PSS and 10 underwent DSRS (Table 1). The cause of liver disease
and demographics of the shunt recipients are displayed in Table 1.
Surgical shunts were performed electively in all but one patient.
Patient 4 presented with uncontrollable upper gastrointestinal
bleeding which failed sclerotherapy and Sengstaken–Blakemore
tube placement. An emergency mesocaval shunt was performed
using the iliac vein of a deceased donor between the superior
mesenteric vein and the inferior vena cava. Patient 12, who had
autoimmune hepatitis, inflammatory bowel disease and associ-
ated lymphoma, developed ascites and thrombocytopenia. He
underwent a proximal splenorenal shunt with splenectomy at the
request of the haemoncology team to facilitate chemotherapy.









Figure 1 Schematic view of mesenterico–left portal vein (Rex)
bypass using the patient's right internal jugular vein
HPB 253
HPB 2009, 11, 252–257 © 2009 International Hepato-Pancreato-Biliary Association
Table 2. All shunt recipients in this category, other than patients 4
and 12, had stable compensated liver disease with preserved syn-
thetic function. Low albumin was noted acutely in association
with gastrointestinal bleeding and was >3 mg/dl preceding the
bleeding episode in all patients except 4 and 12.
Extrinsic portal hypertension
Ten patients had portal vein thrombosis (PVT) and required PSS
or Rex bypass secondary to gastrointestinal bleeding refractory to
medical treatment including sclerotherapy or band ligation. Two
developed thrombosis of the portal vein after LTx and required
DSRS secondary to hypersplenism with or without gastrointesti-
nal bleeding post-LTx. All children had magnetic resonance
imaging (MRI) to assess vascular anatomy before surgery. Three
children, all <10 years of age, with PVT in whom the intrahepatic
portion of the portal vein was patent on MRI received a Rex
bypass. One of the 10 had pro-coagulant status and his shunt
thrombosed despite anticoagulation; splenic artery embolization
was subsequently performed. The remaining nine children were
stable at last follow-up, with no recurrence in gastrointestinal
bleeding.
Three patients with tense refractory ascites were referred to
our centre. The first had acute onset abdominal swelling and
was ultimately diagnosed with Budd–Chiari syndrome (post-
Table 1 Demographics, diagnoses, types of portosystemic shunt and outcomes in children with intrinsic liver disease







1 M Biliary atresia 2.8 DSRS 1.2 Patent shunt
2 M Biliary atresia 3.9 DSRS 0.2 Patent shunt
3 F Biliary atresia 5.5 DSRS 0.2 Patent shunt
4 M Biliary atresia 8.8 Mesocaval 14.1 Liver transplant
5 M Congenital hepatic fibrosis 16.7 DSRS 11.7 Liver transplant
6 M Congenital hepatic fibrosis 6.4 DSRS 1.1 Patent shunt
7 M Cryptogenic cirrhosis 18.0 DSRS 5.8 Patent shunt
8 F Cryptogenic cirrhosis 22.1 DSRS 3.6 Patent shunt
9 F Autoimmune hepatitis 18.6 DSRS 6.1 Death (non-adherence)
10 M Wilson's disease 10.7 DSRS 0.3 Patent shunt
11 F Cystic fibrosis 12.9 DSRS 4.7 Patent shunt
12 M Lymphoma 17.9 Proximal splenorenal 0.2 Death secondary
to lymphoma
M, male; F, female; DSRS, distal splenorenal shunt
Table 2 Liver function tests in children with intrinsic liver disease who received a surgical portosystemic shunt










1 Biliary atresia 1.2 1.8a 137 1.0 0.4 42
2 Biliary atresia 1.2 4.3 136 0.4 0 93
3 Biliary atresia 1.5 2.1a 135 0.6 0.2 97
4 Biliary atresia 1.3 2.5b 141 9.8b N/A 81
5 Congenital hepatic fibrosis 1.2 4.2 138 1.7 0.4 110
6 Congenital hepatic fibrosis 1.2 3.8 138 0.2 0.4 81
7 Cryptogenic cirrhosis 1.3 3.7 139 2.9 1.7 59
8 Cryptogenic cirrhosis 1.6 2.9a 141 1.5 0.7 37
9 Autoimmune hepatitis 1.3 4.3 130 1.4 0.3 49
10 Wilson's disease 1.5 3 137 2.5 0.7 80
11 Cystic fibrosis 1.3 3.3 140 0.6 0.2 102
12 Lymphoma 1.3 2.1c 137 5.4c 5.2 50
aLow albumin was noted acutely in association with gastrointestinal bleeding and was >3 mg/dl preceding the bleed and during follow-up after the
surgical shunt procedure
bPatient 4 had an emergency mesocaval shunt for a gastrointestinal bleed that could not be controlled medically
cPatient 12 had a portosystemic shunt to facilitate chemotherapy for lymphoma
INR, international normalized ratio; N/A, not available
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sinusoidal portal hypertension) after imaging and liver biopsy
locally. Magnetic resonance studies showed clotting of hepatic
veins and the inferior vena cava, but the portal vein and hepatic
artery were patent. This patient was also noted to have recurrent
mouth ulcers, low protein C and was later diagnosed with
Behçet’s disease. Serum transaminase levels were <50 IU/l, total
bilirubin was 1.5 mg/dl and prothrombin time 17 s. A mesoatrial
shunt was performed for relief of refractory ascites and immu-
nosuppressants administered for treatment of Behçet’s disease. A
young woman, with a history of taking herbal medications and
oral contraceptives, presented with increasing abdominal disten-
sion and was diagnosed with Budd–Chiari syndrome. She had
normal synthetic function with no cholestasis and received a
mesocaval shunt. The last patient with Budd–Chiari syndrome
was noted to have high-grade stenosis in the superior portion of
the intrahepatic vena cava and hepatic veno-occlusive disease.
He had recurrence of stenosis despite angioplasty twice locally
and was referred to our centre for surgical shunt. A mesoatrial
shunt was performed and his problems with ascites have
resolved. Three children with hepatoportal sclerosis had DSRS
secondary to gastrointestinal bleeding (two failed sclerotherapy
and the third had massive gastric varices). All three were
stable at last follow-up with no recurrence in bleeding or need
for LTx.
Four patients with familial hypercholesterolaemia and absent
low-density lipoprotein receptor had a portacaval shunt.11 The
time required to reach a plateau in cholesterol lowering of 30–50%
after shunt was approximately 6 months. The children also
received apheresis, and all but one are on oral lipid-lowering
agents (atorvastatin and ezetimibe). One has required replace-
ment of her aortic valve and is on the heart and liver transplant
list. Another has uncontrolled hypertension with asymptomatic
single vessel coronary disease and the remaining two have
minimal coronary artery disease.
None of the shunt recipients showed evidence of overt
encephalopathy and all were attending school normally. No
detailed testing had been performed to detect low-grade or sub-
clinical encephalopathy in the longterm and it is possible that
subtle neurocognitive or fine motor defects were missed. At last
follow-up, at a median of 2.9 years (range 0.1–14.1 years), 27 of 32
were alive with a functioning shunt and had not required LTx
after shunt surgery. Only one shunt was thrombosed. Two patients
required LTx, of whom one had congenital hepatic fibrosis and
required LTx secondary to recurrent cholangitis 8 years after the
shunt, and the other, five days after undergoing emergency meso-
caval shunt for life threatening gastrointestinal bleeding second-
ary to portal hypertension associated with biliary atresia. There
were two deaths unrelated to PSS. One subject (patient 12) suc-
cumbed to lymphoma and the second (patient 9) to complications
of end-stage liver disease. The latter was extremely non-adherent
and not considered to be a suitable candidate for LTx. All four
were noted to have a patent shunt at the last imaging study before
death or transplant.
Discussion
This is one of the largest single-centre series illustrating the
important role of surgical PSS and Rex bypass in paediatrics. Over
a period of 15 years, 32 paediatric patients have undergone surgi-
cal procedures excluding LTx for complications related to portal
hypertension and familial hypercholesterolaemia. The types of
surgical procedures included DSRS, portacaval, proximal spleno-
renal, mesocaval and mesoatrial shunts and, more recently, the
Rex bypass. The outcome has been excellent, with shunt occlusion
in one and LTx in two patients.
The most important indication for PSS in our series was intrin-
sic liver disease with gastrointestinal haemorrhage refractory to
medical treatment, endoscopic banding or sclerotherapy. Typi-
cally, these children are listed for and receive LTx in many centres.
Avoiding or postponing LTx, especially in the current climate of
organ shortage, is extremely valuable. The 12 children with intrin-
sic liver disease who had a surgical shunt rather than being listed
for LTx had compensated liver disease. They were selected care-
fully based on the results of their liver function tests. Liver trans-
plant was the preferred option for children with ascites, increasing
cholestasis or any other evidence of decompensation of liver
disease. All but one shunt recipient had good synthetic function of
the liver and 10 of the 12 patients had serum direct bilirubin
<2 mg/dl. Miga and colleagues reported that patients with biliary
atresia and a serum bilirubin concentration <4 mg/dl at the first
episode of variceal bleeding had a transplant-free survival rate of
>80% for 4 years after this episode, and that 50% of those with
bilirubin levels of 4–10 mg/dl were alive at 1 year, whereas survival
in those with bilirubin levels >10 mg/dl was 50% at 4 months.13
Thus, the bilirubin level is of prognostic significance in biliary
atresia: children with total bilirubin of <4 mg/dl are candidates for
shunts, whereas those with higher bilirubin levels might be better
served by transplant. The two patients with bilirubin >4 mg/dl
who received a PSS in our series were not conventional shunt
candidates.
In paediatric practice, a child with gastrointestinal bleeding
secondary to portal hypertension despite endoscopic treatment is
most likely to require shunt surgery. Traditionally, children with
extrahepatic portal hypertension secondary to PVT have been
the most common recipients of PSS. Two children in this series
received PSS after LTx as they developed PVT-related complica-
tions after LTx.Medical treatment for variceal bleeding potentially
includes beta-blockers and sclerotherapy/band ligation.When this
fails, available treatment options include TIPS, shunt surgery and
LTx. Henderson and colleagues reported the results of DIVERT, a
multicentre study with 140 enrolled adult patients that compared
TIPS with DSRS. Although survival rates were similar in both
groups, rates of re-intervention, stenosis and thrombosis were
significantly higher in the TIPS group compared with the DSRS
group.14 However, TIPS can be technically difficult to perform in
small children;5 in another paediatric series,15 only two of nine
children in whom TIPS was attempted had a functioning shunt at
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last follow-up. In our series, 15 children were aged <10 years at the
time of the shunt surgery and eight of 15 were aged <5 years. In
young children with PVT, shunt surgery was therefore considered
the treatment of choice and TIPS was not performed in any chil-
dren in this series. Hepatoportal sclerosis in childhood mimics
extrahepatic portal vein obstruction and is a cause of non-
cirrhotic portal hypertension. The portal pressure measurements
are suggestive of a pre-sinusoidal block, but a patent portal vein is
demonstrated on angiography. Typically, there is abrupt narrow-
ing of the intrahepatic portal branches, giving a ‘withered tree’
appearance.16 Characteristically, patients have symptoms of portal
hypertension, but have preserved synthetic function of the liver.17
The three children in our series with hepatoportal sclerosis in
whom surgical PSS was performed have not required LTx at last
follow-up. Budd–Chiari syndrome is defined as non-cardiogenic
hepatic venous outflow obstruction that results in ascites and liver
enlargement.18 Medical therapy includes diuresis and treatment of
predisposing factors. Percutaneous transhepatic angioplasty and
venous stent placement have been successful in a small number of
patients. Although TIPS has been used in adults, experience with
the procedure in children is limited.19 Surgical portosystemic
shunting to decompress portal hypertension caused by hepatic
venous obstruction is well tolerated.20 Two patients in this series
required mesoatrial shunting and one had a mesocaval shunt. All
three had good synthetic function of the liver and were therefore
not considered suitable candidates for LTx.
Familial hypercholesterolaemia is a historical indication for PSS
in our centre and portacaval shunts were performed in four chil-
dren before the year 2000. In the early 1980s, Starzl et al. reported
that portacaval shunts performed in subjects with familial hyper-
cholesterolaemia reduced the total serum cholesterol by 20–55%,
and resulted in the reduction or disappearance of xanthomas and
improvement in the growth of children, but data on the reversal of
cardiovascular lesions were inconclusive.12 Subsequently, other
forms of therapy have evolved, including plasmapheresis,21 statins,
ezetimibe and LTx.22 Although portacaval shunts have an imme-
diate hypolipaemic effect,23 this effect may be insufficient. Previ-
ous shunting canmake LTx technically more difficult later in life;24
however, this has not been our experience.
The decision to perform a certain type of shunt depended on
the indication for surgical shunt, the vascular anatomy of the
subject and the time-frame. The DSRS was the procedure of
choice in children with complications related to portal hyper-
tension, in whom a surgical shunt was planned, as it allowed
selective decompression of the variceal bed and preservation of
the spleen. Mesocaval shunt was performed emergently in only
one child with uncontrollable bleeding secondary to portal
hypertension as a life-saving procedure. The first Rex bypass was
performed in this series in children with extrahepatic portal
hypertension in December 2004; three children received a Rex
bypass. Only children who had a patent intrahepatic branch of
the portal vein on MRI were considered suitable candidates for
the Rex bypass. The decision about whether the Rex bypass pro-
cedure was feasible was made according to portal venography
carried out in the operating room. Regardless of the diameter of
the intrahepatic portal vein branches, if both right and left portal
branches were patent, Rex bypass was performed. The Rex bypass
is not indicated in children with intrinsic liver disease and patent
portal vein. Proximal splenorenal shunt was performed in one
child with lymphoma in whom splenectomy had been requested
by the referring haemoncologist to facilitate chemotherapy. Por-
tacaval shunts were performed only for hypercholesterolaemia in
this series. The procedure of choice in Budd–Chiari syndrome
was mesocaval shunt. Mesoatrial shunt had to be performed in
two patients with Budd–Chiari syndrome in whom mesocaval
shunt was technically not feasible as there was thrombosis in the
vena cava.
In conclusion, PSS and the Rex bypass have important roles in
the management of severe portal hypertension in children. Both
DSRS and the Rex bypass can be used successfully to manage
extrahepatic portal hypertension, particularly in small children in
whom TIPS may be technically difficult. The outcome has been
excellent in this series, with no mortality associated with the pro-
cedure and shunt occlusion in only one recipient at last follow-up.
Portosystemic shunt was palliative in candidates with cirrhosis
and portal hypertension who were not transplant candidates sec-
ondary to non-adherence, alcohol or drug addiction. Of note, in
our centre, surgical PSS was used successfully in children with
compensated cirrhosis to delay or avoid transplantation. Near-
term morbidity and mortality from the underlying liver disease
must be carefully considered in the decision-making process. In
light of the organ shortage, PSS should continue to be considered
as a component in the management strategy of children with
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